That’s just it, the risk reward does not make sense to be short…their conviction might be it goes to zero and they never have to return the shares. I judge that highly improbable. Just remember we are on the other side of that trade. Their large and injurious loss is now your gain. I have never sold a share with an equally strong conviction that true value always comes out in the end. That value also transcends money, which is just a means of exchange. Many with cancer will gladly exchange money for a cure, and clinically justifiable hope. The discovery of penicillin is estimated to have saved 200 million lives. How many will Leronlimab save? What is that worth? We will find out in due course as value by turns is revealed. My sense is the near-term quiet downstream of ESMO is because these questions are of interest not only to Cytodyn but to other parties who understand value…and have the means of exchange.